Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$27.93−0.12 (-0.43%)
Close on Nov 20, 2026Market cap $4.46BP/E –Yield –
Adaptive Biotechnologies gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Adaptive Biotechnologies's gross profit for the twelve months ending Jun 30, 2026 was $232.83M, up 71.8% year over year. For fiscal 2025 it was $205.62M, up 92.4% from the year before. The highest annual figure on record is $205.62M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $205.62M | +92.4% |
| FY2024 | Dec 31, 2024 | $106.88M | +12.8% |
| FY2023 | Dec 31, 2023 | $94.72M | -25.6% |
| FY2022 | Dec 31, 2022 | $127.40M | +21.3% |
| FY2021 | Dec 31, 2021 | $105.04M | +38.5% |
| FY2020 | Dec 31, 2020 | $75.85M | +20.8% |
| FY2019 | Dec 31, 2019 | $62.80M | +74.5% |
| FY2018 | Dec 31, 2018 | $36.00M | +58.1% |
| FY2017 | Dec 31, 2017 | $22.77M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $51.39M | +25.7% |
| Q1 FY2026 | Mar 31, 2026 | $52.17M | +47.1% |
| Q4 FY2025 | Dec 31, 2025 | $53.46M | +81.7% |
| Q3 FY2025 | Sep 30, 2025 | $75.82M | +154.7% |
| Q2 FY2025 | Jun 30, 2025 | $40.88M | +71.2% |
| Q1 FY2025 | Mar 31, 2025 | $35.46M | +48.9% |
| Q4 FY2024 | Dec 31, 2024 | $29.41M | +12.4% |
| Q3 FY2024 | Sep 30, 2024 | $29.77M | +60.3% |
| Q2 FY2024 | Jun 30, 2024 | $23.87M | -23.0% |
| Q1 FY2024 | Mar 31, 2024 | $23.82M | +25.6% |
| Q4 FY2023 | Dec 31, 2023 | $26.17M | -32.2% |
| Q3 FY2023 | Sep 30, 2023 | $18.57M | -43.6% |
| Q2 FY2023 | Jun 30, 2023 | $31.02M | +1.9% |
| Q1 FY2023 | Mar 31, 2023 | $18.97M | -25.4% |
| Q4 FY2022 | Dec 31, 2022 | $38.61M | +63.8% |
| Q3 FY2022 | Sep 30, 2022 | $32.92M | +30.2% |
| Q2 FY2022 | Jun 30, 2022 | $30.44M | +9.7% |
| Q1 FY2022 | Mar 31, 2022 | $25.43M | -10.6% |
| Q4 FY2021 | Dec 31, 2021 | $23.57M | -1.6% |
| Q3 FY2021 | Sep 30, 2021 | $25.28M | +24.9% |
| Q2 FY2021 | Jun 30, 2021 | $27.74M | +72.6% |
| Q1 FY2021 | Mar 31, 2021 | $28.45M | +82.8% |
| Q4 FY2020 | Dec 31, 2020 | $23.96M | +31.2% |
| Q3 FY2020 | Sep 30, 2020 | $20.25M | -1.0% |
| Q2 FY2020 | Jun 30, 2020 | $16.08M | -2.0% |
| Q1 FY2020 | Mar 31, 2020 | $15.57M | +102.7% |
| Q4 FY2019 | Dec 31, 2019 | $18.26M | +53.2% |
| Q3 FY2019 | Sep 30, 2019 | $20.46M | +73.0% |
| Q2 FY2019 | Jun 30, 2019 | $16.40M | +151.4% |
| Q1 FY2019 | Mar 31, 2019 | $7.68M | – |
| Q4 FY2018 | Dec 31, 2018 | $11.92M | – |
| Q3 FY2018 | Sep 30, 2018 | $11.83M | – |
| Q2 FY2018 | Jun 30, 2018 | $6.52M | – |
See a number that looks wrong?